# Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E

> **NCT00761501** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 38 (estimated)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** PN400
- **DRUG:** Naproxen (Proxen S)
- **DRUG:** Naproxen (Naprosyn E)

## Key facts

- **NCT ID:** NCT00761501
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2010-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761501, "Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00761501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*